SUBSCRIBE
SUBSCRIBE
News   Drug Development

New Data Shows Promise of German Merck KGaA’s MS Drug

September 11, 2009 | 
1 min read
Bookmark and Share

Reuters -- A new analysis of data from a clinical trial of Merck KGaA's oral drug cladribine has underscored its potential as a treatment for multiple sclerosis, researchers said on Friday.
Clinical research Phase III
MORE ON THIS TOPIC
Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VII
Obesity
Lilly Plots Path to FDA After Second Phase III Readout for Orforglipron
August 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Rare diseases
Argenx Eyes ‘Broadest Label’ for Vyvgart in Myasthenia Gravis After Positive Phase III Data
August 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations
August 26, 2025
 · 
1 min read
 · 
Jef Akst
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Regulatory
Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway
August 22, 2025
 · 
2 min read
 · 
Tristan Manalac